TY  - JOUR
AU  - Kanaan, Manal Hadi Ghaffoori
AU  - Tarek, Ahmad M.
AU  - Lee, Beom-Jin
AU  - Abdullah, Sura Saad
AU  - Park, Chulhun
AU  - Ghasemian, Abdolmajid
AU  - Mudenda, Steward
PY  - 2026
DA  - 2026/05/18
TI  - A Multi-Omics Panorama of Acute Myeloid Leukemia: From Molecular Hallmarks to Clinical Translation
JO  - OBM Genetics
SP  - 340
VL  - 10
IS  - 02
AB  - Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with genetic and clinical characteristics. Recent advances in multi-omic technologies, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, immunomics, microbiome profiling, and both spatial and single-cell analyses, have greatly enhanced our understanding of AML pathobiology. Substantial multi-omic studies show that recurrent driver mutations not only impart traditional genomic lesions but also participate in chromatin restructuring, transcriptional and splicing program alterations, host metabolism, and immune evasion mechanisms. Transcriptomic subclassification has improved AML classification beyond cytogenetic and mutational systems, while proteogenomic profiling has elucidated the mechanisms of chemotherapy resistance and provided new druggable targets. The use of metabolomic and immunometabolomic approaches has illuminated nutrient dependencies and metabolic vulnerabilities, while spatial/single-cell multi-omics has revealed unprecedented detail about leukemic heterogeneity and bone marrow niche organization. Multi-omics has also helped establish or refine prognostic models, identify candidate biomarkers, develop patient stratification strategies, and design targeted and immune-based therapies. The multi-omics approach provides a mechanism to rationalize the complex molecular, cellular, and microenvironmental nature of AML and represents a pathway for precision medicine, provided that methodological harmonization, large-scale rigorous validation, and equitable clinical adoption of these approaches can be achieved.
SN  - 2577-5790
UR  - https://doi.org/10.21926/obm.genet.2602340
DO  - 10.21926/obm.genet.2602340
ID  - Kanaan2026
ER  -